Medical Policy and and and and
|
|
- Roger Edwards
- 5 years ago
- Views:
Transcription
1 ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 93799, Unlisted cardiovascular service or procedure Medical Policy Title: Percutaneous Transluminal Septal Myocardial Ablation Document: ARB0341 Administered by: Public Statement: 1) Percutaneous Transluminal Septal Myocardial Ablation (PTSMA), also known as Transcoronary Ablation of Septal Hypertrophy (TASH), is a minimally invasive treatment of an unusual form of cardiomyopathy. 2) PTSMA is done to improve the heart's ability to pump blood when the septum has become enlarged and thickened from Hypertrophic Obstructive Cardiomyopathy (HOCM). The septum is the heart muscle that separates the right and left ventricles of the heart. The septal enlargement and thickening blocks the heart from being able to pump blood out efficiently. HOCM may cause symptoms such as chest pain, shortness of breath, and dizziness, especially with exertion. HOCM may even cause sudden death. 3) PTSMA is subject to review for medical necessity. Medical Policy Statement: 1) Percutaneous Transluminal Septal myocardial ablation (PTSMA) by alcohol-induced septal branch occlusion is considered medically necessary for hypertrophic obstructive cardiomyopathy (HOCM) in adults when all of the following criteria are met: a) Member has severe symptoms (e.g., dyspnea, angina pectoris, [pre]syncope, palpitations or heart failure) despite optimal drug therapy (e.g., beta-blockers, calcium-antagonists), dual chamber pacing (DDD) therapy and/or ineffective previous surgical myotomy/myectomy; and b) Member is classified as New York Heart Association class III or IV ; and c) Member has a classical, asymmetric subaortic HOCM identified by echocardiography (ECHO), and not other forms of cardiomyopathy; and d) ECHO shows left ventricular wall thickness of greater than 13 mm in adults in the absence of another cause for left ventricular hypertrophy (LVH); and Page 1 of 5
2 e) Member has systolic anterior motion of the mitral valve on ECHO; and f) Member has a resting left ventricular outflow tract (LVOT) gradient of greater than 30 mm Hg or a stressed gradient of greater than 60 mm Hg, or member has less severe symptoms and LVOT of greater than 50 mm Hg at rest or greater than 100 mm Hg under stress; and g) Member does not have coronary artery disease (CAD) that would preclude performance of the procedure. HAYES B The Stages of Heart Failure NYHA Classification In order to determine the best course of therapy, physicians often assess the stage of heart failure according to the New York Heart Association (NYHA) functional classification system. This system relates symptoms to everyday activities and the patient's quality of life. Class Class I (Mild) Class II (Mild) Class III (Moderate) Class IV (Severe) Patient Symptoms No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased. Limits: Percutaneous transluminal septal myocardial ablation is considered experimental and investigational for all other indications. Background: 1) Hypertrophic obstructive cardiomyopathy (HOCM), also known as idiopathic hypertrophic subaortic stenosis (IHSS), is a primary, sometimes familial and Page 2 of 5
3 genetically determined myocardial hypertrophy with an incidence of about 0.2%. About 25% of the patients have dynamic left ventricular outflow tract (LVOT) obstruction, which usually develops during puberty and increases in severity until the age of 18 to 20 years. Not infrequently, HOCM is diagnosed for the first time in the elderly. 2) This condition is characterized by a super-normally contracting left ventricle, asymmetric septal hypertrophy, which affects mainly the interventricular septum, increased ventricular wall thickness (left ventricular wall thickness of > 13 mm in adults in the absence of another cause for left ventricular hypertrophy (LVH); 15 mm in an athlete), and systolic anterior motion of the mitral valve. 3) Asymptomatic adult patients probably do not require therapy or risk stratification studies, unless there is a malignant family history of sudden death or occupational need (airline pilot). Management decisions are dominated by the need to address sometimes disabling symptoms of dyspnea, angina pectoris, stress-induced syncope, palpitations or heart failure, and risk of sudden death. Treatment of symptomatic patients with HOCM aims at reduction of the left ventricular outflow tract gradient and improvement of diastolic filling either by pharmacological therapy with negative inotropic drugs (beta-blockers, calcium-antagonists), permanent DDD pacemaker therapy (i.e., dual chamber, dual pacing, dual sensing), or surgical myotomy/myectomy. 4) Left ventricular myotomy and myectomy (Morrow's procedure) has been the standard therapy for patients with severe symptoms (New York Heart Association functional class III-IV) that persist despite adequate pharmacotherapy and DDD pacing. 5) In 1994, as an alternative to surgery, non-surgical Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) by alcohol-induced septal branch occlusion was introduced to decrease left ventricular outflow tract (LVOT) gradient and improve symptoms in patients with HOCM. This method was substantially improved by the introduction of echocardiographic guidance in ) PTSMA involves transcatheter selection of one or two small septal branches of the left anterior descending artery, threading a small, short, low-pressure angioplasty balloon into position to occlude the artery, and the instillation of absolute alcohol into the myocardium. The resultant localized myocardial infarction reduces the amount of septal myocardium, opening up the left ventricular outflow tract. Compared with surgical myectomy, the literature shows that PTSMA has the advantage of being minimally invasive, easily repeated, and with relatively low major morbidity/mortality risk for patients with co-morbid conditions. References: 1. Hayes Inc, Medical Technology Directory; Alcohol ablation for obstructive cardiomyopathy, Jan Page 3 of 5
4 2. Spirito P. Alcohol septal ablation in the management of obstructive hypertrophic cardiomyopathy. Ital Heart J. 2000;1(11): Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet. 2000;355(9202): Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep. 2001;3(2): Kim JJ. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83(8): Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol. 2000;89(Suppl 4):IV41-IV Faber L. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients. Heart. 2000;83(3): Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep. 2001;3(2): Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001;38(7): Mutlak D, Gruberg L, Reisner S, et al. Non-surgical myocardial reduction in hypertrophic obstructive cardiomyopathy. Isr Med Assoc J. 2002;4(2): Jiang T, Wu X, Jia C, et al. Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy. Chin Med J (Engl). 2002;115(1): Kovacic JC, Muller D. Hypertrophic cardiomyopathy: State-of-the-art review, with focus on the management of outflow obstruction. Intern Med J. 2003;33(11): National Institute for Clinical Excellence (NICE). Interventional procedure overview of non-surgical reduction of myocardial septum. London, UK: NICE; November Available at: Accessed September 13, Li ZQ, Cheng TO, Zhang WW, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: The Chinese experience in 119 patients from a single center. Int J Cardiol. 2004;93(2-3): Veselka J, Prochazkova S, Duchonova R, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv. 2004;63(2): National Institute for Clinical Excellence (NICE). Non-surgical reduction of myocardial septum. Interventional Procedure Guidance 40. London, UK: NICE; February Available at: Accessed September 13, Page 4 of 5
5 17. van der Lee C, ten Cate FJ, Geleijnse ML, et al. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation. 2005;112(4): Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Inter Cardiol Aug.; 19(4); Application to Products This policy applies to ARBenefits. Consult ARBenefits Summary Plan Description (SPD) for additional information. Last modified by: Date: Page 5 of 5
Prior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationThe 2014 Mayo Approach to the Management of HCM and Non-Compaction
The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-1 Let
More informationORIGINAL PAPER. R. C. Steggerda & J. C. Balt & K. Damman & M. P. van den Berg & J. M. ten Berg
Neth Heart J (2013) 21:504 509 DOI 10.1007/s12471-013-0453-4 ORIGINAL PAPER Predictors of outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Special interest
More informationmarked increase in thickness of walls of heart in patient with HCM.
Surgical Management of Hypertrophic Obstructive Cardiomyopathy Hani K. Najm MD, Msc, FRCSC, FRCS (Glasg Glasg), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi
More informationCase Presentation: A 58-yearold
CLINICIAN UPDATE Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Carey D. Kimmelstiel, MD; Barry J. Maron, MD Case Presentation: A 58-yearold diabetic man was referred for
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationCardiomyopathy Consequences. function of the myocardium for any reason. This is a serious disease in which the heart muscle
Becki Simmons Cardiomyopathy Consequences Cardiomyopathy, which literally means "heart muscle disease," is the deterioration of the function of the myocardium for any reason. This is a serious disease
More informationSteel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015
Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant
More informationAlcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)?
Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)? Sarang Mangalmur+, MD Bryn Mawr Hospital, PA NCVH New Jersey 2015 Disclosures No relevant disclosures
More informationTreatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD
Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)
More informationEndocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy
Journal of the American College of Cardiology Vol. 57, No. 5, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.07.055
More informationThe Management of HOCM: What are the Surgical Options
The Management of HOCM: What are the Surgical Options Konstadinos A Plestis, MD System Chief of Cardiac Thoracic and Vascular Surgery Main Line Health Care System Professor Sidney Kimmel Medical College
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationPatients with hypertrophic cardiomyopathy (HCM) and an
Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions
More informationL Faber, A Meissner, P Ziemssen, H Seggewiss
326 Heart 2000;83:326 331 Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients L Faber, A Meissner, P
More informationInterventional Imaging Cases
Interventional Imaging Cases Steven A. Goldstein MD Professor of Medicine Georgetown University Medical Center MedStar Heart Institute Washington Hospital Center Tuesday, October 10, 2017 DISCLOSURE I
More informationP atients with hypertrophic cardiomyopathy and an outflow
638 CARDIOVASCULAR MEDICINE Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients F H Gietzen,
More informationCardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center
Cardiac Issues in the Adolescent Athlete Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Sudden Cardiac Death Incidence is.6-6.2 % per 100,000 children in the US 20-25 % of the deaths occur
More informationHYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy
HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure Paolo Spirito, Genoa, Italy Clinical Substrates for Heart Failure Symptoms in HCM Diastolic dysfunction Atrial fibrillation LV outflow obstruction Evolution
More informationHypertrophic Cardiomyopathy: beyond gradient and wall thickness
Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Michael H. Picard, M.D. Massachusetts General Hospital Harvard Medical School no disclosures special thanks to A. Baggish 1 Hypertrophic
More informationCardiomyopathy: The Good, the Bad.and the Insurable?
Cardiomyopathy: The Good, the Bad.and the Insurable? WAHLU Spring Seminar 2014 Joy Geiger, RN, BSN, ALMI Medical Consultant The Northwestern Mutual Life Insurance Company Milwaukee, WI Objectives Overview
More informationCardiac MRI: Cardiomyopathy
Cardiac MRI: Cardiomyopathy Laura E. Heyneman, MD I do not have any relevant financial relationships with any commercial interests Cardiac MRI: Cardiomyopathy Laura E. Heyneman, MD Duke University Medical
More informationConsequences of Cardiomyopathy. thickened and stiff, the left ventricle is most often affected. This results in a lack of pumping
Roseanne Baird March 30, 2010 BI 104 Dr. Hammoudi Consequences of Cardiomyopathy Cardiomyopathy is a disease in which the myocardium of the heart becomes enlarged, thickened and stiff, the left ventricle
More informationCardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death
Cardiac Conditions in Sport & Exercise Dr Anita Green Cardiac Conditions in Sport Sudden Cardiac Death USA - Sudden Cardiac Death (SCD)
More informationISPUB.COM. Hypertrophic Cardiomyopathy. L Hull-Grommesh CLINICAL DESCRIPTION INCIDENCE/PREVALENCE
ISPUB.COM The Internet Journal of Advanced Nursing Practice Volume 10 Number 2 L Hull-Grommesh Citation L Hull-Grommesh.. The Internet Journal of Advanced Nursing Practice. 2008 Volume 10 Number 2. Abstract
More informationHypertrophic obstructive cardiomyopathyalcoholseptalablationvs.myectomy:a
European Heart Journal (2009) 30, 1080 1087 doi:10.1093/eurheartj/ehp016 CLINICAL RESEARCH Heart failure/cardiomyopathy Hypertrophic obstructive cardiomyopathyalcoholseptalablationvs.myectomy:a meta-analysis
More informationHypertrophic Obstructive Cardiomyopathy
The new england journal of medicine clinical practice Hypertrophic Obstructive Cardiomyopathy Rick A. Nishimura, M.D., and David R. Holmes, Jr., M.D. This Journal feature begins with a case vignette highlighting
More informationWhat s new in Hypertrophic Cardiomyopathy?
What s new in Hypertrophic Cardiomyopathy? Dr Andris Ellims HCM Clinic @ The Alfred Hypertrophic Cardiomyopathy = otherwise unexplained LV hypertrophy* 1 in 500 prevalence most common inherited cardiovascular
More informationCoincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy, and significance of magnetic resonance in its diagnostics
cor et vasa 55 (2013) e271 e276 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/crvasa Case Report Coincidence of bicuspid aortic valve presence and hypertrophic cardiomyopathy,
More informationAlcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. CardioVascular Research Foundation
Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Alcohol Septal Ablation (ASA) Nonsurgical technique for septal myocardial reduction Dramatic hemodynamic improvement Technically easy
More informationHEART CONDITIONS IN SPORT
HEART CONDITIONS IN SPORT Dr. Anita Green CHD Risk Factors Smoking Hyperlipidaemia Hypertension Obesity Physical Inactivity Diabetes Risks are cumulative (multiplicative) Lifestyles predispose to RF One
More informationEffect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 5, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.07.004 Effect of
More informationSeptal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report
Case Report Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report Junichiro Takahashi, MD, 1 Yutaka Wakamatsu, MD, 1 Jun Okude,
More informationHOCM: Alcohol ablation or LVOT Surgery: When and what?
HOCM: Alcohol ablation or LVOT Surgery: When and what? Paul R Vogt/ Pascal A. Berdat Cardiovascular Center Zurich Clinic Im Park Zurich SKG/SGHC Annual Meeting, Zurich, 10.-12.6.15 ASA/Myectomy: Common
More informationHypertrophic Cardiomyopathy
019-CardioCase:019-CardioCase 4/16/07 1:39 PM Page 19 Hypertrophic Cardiomyopathy Abdullah Alshehri, MD; and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Presley s check-up Presley, 37, discovered
More informationThe Management of Hypertrophic Cardiomyopathy
The Management of Hypertrophic Cardiomyopathy Evidence and Uncertainties Banff 2013 3058464-0 Management of HCM Key Elements Screen 1 relatives for HCM Serial Echo Genetic testing Assess risk for and prevent
More informationEtiology, Classification & Management. Sheba Medical Center Cardiology Department Matthew Wright St. George s University of London
Etiology, Classification & Management Sheba Medical Center Cardiology Department Matthew Wright St. George s University of London Introduction World Health Organization (1995): Diseases of myocardium (heart
More informationInspiratory Right Ventricular Outflow Obstruction in a Patient with Hypertrophic Cardiomyopathy
Case Reports Inspiratory Right Ventricular Outflow Obstruction in a Patient with Hypertrophic Cardiomyopathy Kazufumi TSUCHIHASHI, M.D., Akihito TSUCHIDA, M.D., Nobuichi HIKITA, M.D., Shuji YONEKURA, M.D.,
More informationCardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement
Cardiomyopathy Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement Nebraska Home Office Life Underwriters Association March 20, 2018 1 Cardiomyopathy A myocardial disorder in which
More informationManagement of HOCM: Non-Surgical Options
Management of HOCM: Non-Surgical Options Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director,
More informationAlcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert
University of Groningen Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationMy Patient Needs a Stress Test
My Patient Needs a Stress Test Amy S. Burhanna,, MD, FACC Coastal Cardiology Cape May Court House, New Jersey Absolute and relative contraindications to exercise testing Absolute Acute myocardial infarction
More informationHypertrophic Cardiomyopathy: basics and management
Hypertrophic Cardiomyopathy: basics and management Bette Kim, MD Program Director, Cardiomyopathy Program Director, Roosevelt Hospital Echocardiography Lab Assistant Professor of Clinical Medicine Mount
More informationHow NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto
How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto Introduction Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy,
More informationUniversity of Groningen. Alcohol septal ablation Liebregts, Max
University of Groningen Alcohol septal ablation Liebregts, Max IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationSeptal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy
European Heart Journal (2002) 23, 1617 1624 doi:10.1053/euhj.2002.3285, available online at http://www.idealibrary.com on Septal myotomy myectomy and transcoronary septal alcohol ablation in hypertrophic
More informationPercutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up in 25 Patients
252 CLINICAL STUDIES JACC Vol. 31, No. 2 HYPERTROPHIC CARDIOMYOPATHY Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-Up
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationAnaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)
Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Dr. Siân Jaggar Consultant Anaesthetist Royal Brompton Hospital London UK Congenital Cardiac Services
More informationInfluence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy
ORIGINAL ARTICLE 5 RAAS inhibitors should be avoided if possible in patients with obstructive HCM Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy Katrin Witzel,
More informationSummary. Introduction
J Biomed Clin Res Volume 8 Number 2, 2015 Review Review ALCOHOL SEPTAL ABLATION Desislava P. Petrova, Sotir T. Marchev, Boyko D. Kuzmanov Specialized Hospital for Active Treatment in Cardiology, Pleven
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationDecember 2018 Tracings
Tracings Tracing 1 Tracing 4 Tracing 1 Answer Tracing 4 Answer Tracing 2 Tracing 5 Tracing 2 Answer Tracing 5 Answer Tracing 3 Tracing 6 Tracing 3 Answer Tracing 6 Answer Questions? Contact Dr. Nelson
More informationHYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE
HYPERTROPHIC CARDIOMYOPATHY (HCM) PRESENTED AS UNSTABLE ANGINA COMPLICATED BY SERIOUS VENTRICULAR ARRHYTHMIAS CASE REPORT AND REVIEW LITERATURE Lusyun Kumar Yadav * and Jin li Jun Department of Cardiology,
More informationExercise Test: Practice and Interpretation. Jidong Sung Division of Cardiology Samsung Medical Center Sungkyunkwan University School of Medicine
Exercise Test: Practice and Interpretation Jidong Sung Division of Cardiology Samsung Medical Center Sungkyunkwan University School of Medicine 2 Aerobic capacity and survival Circulation 117:614, 2008
More informationLeft ventricular outflow tract obstruction: indications and limitations of current therapies
Left ventricular outflow tract obstruction: indications and limitations of current therapies Costas O Mahony Inherited Cardiovascular Diseases Unit, The Heart Hospital, London, UK. None to declare Conflicts
More informationHypertrophic Cardiomyopathy Ud Din Shah, MD; DM; FICC; FESC; FACC
3 Article 1 Physicians Academy January 2018 Hypertrophic Cardiomyopathy Mehraj Ud Din Shah, MD; DM; FICC; FESC; FACC Hypertrophic Cardiomyopathy (HCM) is a genetic disorder which causes clinically unexplained
More informationUpdated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.047
More informationSlide 1. Slide 2. Slide 3. Sudden Cardiac Death In Athletes. Epidemiology. Epidemiology. Shaun McMurtry, MD Primary Care Sports Medicine
Slide 1 Sudden Cardiac Death In Athletes Shaun McMurtry, MD Primary Care Sports Medicine Slide 2 Epidemiology College and Professional Athletes 500,000 participants each year Competitive Athletics Estimated
More informationPresenter: Steven Brust, HCS-D, HCS-H Product Manager, Home Health Coding Center
Presenter: Steven Brust, HCS-D, HCS-H Product Manager, Home Health Coding Center Pinpoint & properly assign the appropriate heart failure codes Left- vs. Right-sided Left ventricular failure (LVF) may
More informationLong-Term Follow-up Impact of Dual-Chamber Pacing on Patients with Hypertrophic Obstructive Cardiomyopathy
Long-Term Follow-up Impact of Dual-Chamber Pacing on Patients with Hypertrophic Obstructive Cardiomyopathy HU YUE-CHENG, M.D., PH.D.,*, LI ZUO-CHENG, B.S.,*, LI XI-MING, PH.D., M.D.,* DAVID ZHE YUAN, M.D.,*,
More informationIn the Thick of It: Hypertrophic Cardiomyopathy
In the Thick of It: Hypertrophic Cardiomyopathy Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of Medicine Director, Heart Failure Outreach Department of Medicine, Division of Cardiology Advanced
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationApical Hypertrophic Cardiomyopathy With Hemodynamically Unstable Ventricular Arrhythmia Atypical Presentation
Cronicon OPEN ACCESS Hemant Chaturvedi* Department of Cardiology, Non-Invasive Cardiology, Eternal Heart Care Center & research Institute, Rajasthan, India Received: September 15, 2015; Published: October
More informationUtility of Echocardiography
Hypertrophic Cardiomyopathy and Beyond- Echo Hawaii 2018 Lawrence Rudski MD FRCPC FACC FASE Professor of Medicine Director, Division of Cardiology and Azrieli Heart Center Jewish General Hospital, McGill
More informationMedStar Health considers External Counterpulsation Therapy (ECP) medically necessary for the following indications:
MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MP.107.MH External Counterpulsation Therapy This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP CSNP MedStar
More informationJournal of the American College of Cardiology Vol. 49, No. 3, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 49, No. 3, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.08.055
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More information2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography,
More informationVariability of Left Ventricular Outflow Tract Gradient During Cardiac Catheterization in Patients With Hypertrophic Cardiomyopathy
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 6, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.02.014 Variability
More informationValvular Heart Disease
Valvular Heart Disease MITRAL STENOSIS Pathophysiology rheumatic fever. calcific degeneration, malignant carcinoid disease, congenital mitral stenosis. SLE. The increased pressure gradient across the mitral
More informationSurgical Myectomy for HOCM
Surgical Myectomy for HOCM Volkmar Falk Deutsches Herzzentrum Berlin Different Pathology of HOCM Impact on surgical strategy Said SM Expert Rev Cardiovasc Ther 2013 Different Pathology of HOCM Impact on
More informationNon-surgical reduction of the myocardial septum
NHS National Institute for Clinical Excellence Non-surgical reduction of the myocardial septum Understanding NICE guidance information for people considering the procedure, and for the public February
More informationUpdate on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM
Update on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM Richard G. Bach, MD, FACC, FAHA Professor of Medicine Director, Hypertrophic Cardiomyopathy Center Washington
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationHYPERTROPHIC CARDIOMYOPATHY
HYPERTROPHIC CARDIOMYOPATHY Most often diagnosed during infancy or adolescence, hypertrophic cardiomyopathy (HCM) is the second most common form of heart muscle disease, is usually genetically transmitted,
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationPERCUTANEOUS SEPTAL ABLATION IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
EUROPEAN JOURNAL OF MEDICAL RESEARCH 423 Eur J Med Res (2006) 11: 423-431 I. Holzapfel Publishers 2006 PERCUTANEOUS SEPTAL ABLATION IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY Lothar Faber Department of
More informationC1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders GENERAL ISSUES REGARDING MEDICAL FITNESS-FOR-DUTY 1. These medical standards apply to Union Pacific Railroad (UPRR) employees
More informationPediatrics. Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment. Overview
Pediatrics Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment See online here The most common form of cardiac arrhythmia in children is sinus tachycardia which can be caused by
More informationJournal of the American College of Cardiology Vol. 33, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00673-1 PERSPECTIVE
More informationAlcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert
University of Groningen Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationESC Guidelines on Hypertrophic Cardiomyopathy
2014 version ES Guidelines on Hypertrophic ardiomyopathy Pr Michel KOMAJDA Dept of ardiology HU PTE SALPETRERE University Pierre et Marie urie PARS FRANE European Heart Journal (2014):doi:10.1093/eurheartj/ehu284
More informationCommon Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
More informationIdiopathic Hypertrophic Subaortic Stenosis and Mitral Stenosis
CASE REPORTS Idiopathic Hypertrophic Subaortic Stenosis and Mitral Stenosis Martin J. Nathan, M.D., Roman W. DeSanctis, M.D., Mortimer J. Buckley, M.D., Charles A. Sanders, M.D., and W. Gerald Austen,
More informationcardiomyopathy. INTRODUCTION NONISCHEMIC CARDIOMYOPATHY
FACTS ABOUT Cardiomyopathy INTRODUCTION Ischemic cardiomyopathy typically refers to heart muscle damage that results from coronary artery disease, such as heart attack, Cardiomyopathy is a disease of the
More information4/11/2017. Cardiomyopathy. John Steuter, MD Bryan Heart. Disclosures. No Conflicts. Cardiomyopathy. WHO Classification
Cardiomyopathy John Steuter, MD Bryan Heart Disclosures No Conflicts Cardiomyopathy WHO Classification Anatomy & physiology of the LV 1. Dilated Enlarged Systolic dysfunction 2. Hypertrophic Thickened
More informationClinical Policy: Holter Monitors Reference Number: CP.MP.113
Clinical Policy: Reference Number: CP.MP.113 Effective Date: 05/18 Last Review Date: 04/18 Coding Implications Revision Log Description Ambulatory electrocardiogram (ECG) monitoring provides a view of
More informationHypertrophic Cardiomyopathy: Patient Management in 2018
Hypertrophic Cardiomyopathy: Patient Management in 2018 Mackram F. Eleid, MD Giornate Cardiologeche Torinesi October 26, 2018 2018 MFMER slide-1 Disclosures No relevant financial relationships to disclose
More informationCoexistence of asymmetric septal hypertrophy and aortic valve disease in adults
Thorax, 1979, 34, 91-95 Coexistence of asymmetric septal hypertrophy and aortic valve disease in adults M V J RAJ, V SRINIVAS, I M GRAHAM, AND D W EVANS From the Regional Cardiac Unit, Papworth Hospital,
More informationCARDIOMYOPATHY IN CT. Hans- Christoph Becker Professor of Radiology
CARDIOMYOPATHY IN CT Hans- Christoph Becker Professor of Radiology 1 Cardiomyopathy Heart muscle disease Deterioration of the heart function, heart failure Dyspnea, peripheral edema Risk of arrhythmia,
More information2019 Qualified Clinical Data Registry (QCDR) Performance Measures
2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry
More informationOptions for my no option Patients Treating Heart Conditions Via a Tiny Catheter
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationHYPERTROPHY: Behind the curtain. V. Yotova St. Radboud Medical University Center, Nijmegen
HYPERTROPHY: Behind the curtain V. Yotova St. Radboud Medical University Center, Nijmegen Disclosure of interest: none Relative wall thickness (cm) M 0.22 0.42 0.43 0.47 0.48 0.52 0.53 F 0.24 0.42 0.43
More informationIschemia results from a number of factors: 1. Impaired vasodilator reserve
Hypertrophic Cardiomyopathy (HCM) February 24, 2018 Henry Green, MD, FACC, FACP Clinical Professor of Medicine, Wayne State University http://sites.google.com/site/theheartsite Definition Hypertrophic
More informationCardiac hypertrophy : differentiating disease from athlete
Cardiac hypertrophy : differentiating disease from athlete Ario Soeryo Kuncoro, MD, Cardiologist Echocardiography Division, National Cardiovascular Centre Harapan Kita-Jakarta Departement of Cardiology
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More information